RecruitingNot applicableNCT07441083
Efficacy and Safety of Shatavari Root Extract in Women's Sexual Wellness
Studying Anorectal malformation
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- SF Research Institute, Inc.
- Intervention
- Shatavari (Asparagus racemosus) Root Extract(dietary_supplement)
- Enrollment
- 60 target
- Eligibility
- 20-50 years · FEMALE
- Timeline
- 2026 – 2026
Study locations (1)
- San Francisco Research Institute, San Francisco, California, United States
Collaborators
Ixoreal Biomed Private Limited
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07441083 on ClinicalTrials.govOther trials for Anorectal malformation
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07545967Re-radiotherapy Combined With Chidamide for the Treatment of Recurrent Head and Neck Squamous Cell Carcinoma After RadiotherapyWest China Hospital
- RECRUITINGNCT07438691Outcomes in ARMs: Comparison Between Surgical Techniques in Patients With Perineal or Vestibular Fistula - a Multicenter Italian StudyMeyer Children's Hospital IRCCS
- RECRUITINGNCT07174388A Study in Non-Small Cell Lung CancerN-Power Medicine
- RECRUITINGNANCT07366476Effectiveness of Electrical Stimulation and Biofeedback on Fecal Incontinence in Children With Repaired Anorectal MalformationSinai University
- RECRUITINGPHASE2, PHASE3NCT07369739Golidocitinib Combined With Selinexor for CAEBVDBeijing Friendship Hospital
- RECRUITINGPHASE2NCT07311577Disitamab Vedotin Combined With Platinum and Bevacizumab as First-Line and Maintenance Therapy for HER2-Expressing, HRD-Negative High-Risk Ovarian Cancer: A Multicenter, Non-Randomized, Single-Arm Phase II Clinical StudyJiangsu Cancer Institute & Hospital
- RECRUITINGNANCT07263451Safety and Feasibility of IRE for Early-stage Breast Cancer: a Prospective, Open-Label, Single-Arm, Exploratory StudyTian'an Jiang
- RECRUITINGPHASE2NCT07447570Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCCSecond Affiliated Hospital, School of Medicine, Zhejiang University